Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients

被引:24
作者
Yin, Ji-ye [1 ,2 ,3 ,4 ]
Meng, Xiang-guang [5 ]
Qian, Chen-yue [1 ,2 ,3 ,4 ]
Li, Xiang-ping [6 ]
Chen, Juan [1 ,2 ,3 ,4 ]
Zheng, Yi [1 ,2 ,3 ,4 ]
Liu, Rong [1 ,2 ,3 ,4 ]
Zhou, Hong-hao [1 ,2 ,3 ,4 ]
Liu, Zhao-qian [1 ,2 ,3 ,4 ]
机构
[1] Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China
[2] Cent S Univ, Inst Clin Pharmacol, Changsha 410008, Hunan, Peoples R China
[3] Hunan Key Lab Pharmacogenet, Changsha 410078, Hunan, Peoples R China
[4] Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang 421001, Peoples R China
[5] Zhengzhou 7 Peoples Hosp, Lab Cardiovasc Dis & Drug Res, Zhengzhou 450016, Peoples R China
[6] Cent S Univ, Dept Pharm, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
eIF3a; positive selection; polymorphism; lung cancer; platinum-based chemotherapy; chemotherapy toxicity; Chinese NSCLC patients; LUNG-CANCER PATIENTS; MOLECULAR POPULATION-GENETICS; NATURAL-SELECTION; HUMAN GENOME; SIGNATURES; TRANSLATION; LOCUS;
D O I
10.1038/aps.2014.160
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aim: Eukaryotic translation initiation factor 3 subunit A (eIF3a) plays critical roles in regulating the initiation of protein translation, and eIF3a is highly expressed in lung cancer. In this study, we investigated the association of the positively selected SNPs of eIF3a with the response to and toxicity of platinum-based chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC). Methods: SNP data for eIF3a locus were downloaded from HapMap database. For each SNP, haplotype, LD profile and population differentiation were analyzed. The long-range haplotype (LRH) test was employed to identify positively selected SNPs of eIF3a. A total of 325 NSCLC patients were enrolled and genotyped for these SNPs. Results: Five positively selected (rs1409314, rs4752219, rs4752220, rs7091672 and rs10510050) and 5 non-positively selected SNPs (rs10886342, rs11198804, rs2275112, rs10787899 and rs4752269) were identified in the LRH test. However, none of them was correlated with the platinum-based chemotherapy response. In contrast, 4 of the positively selected SNPs (rs1409314, rs4752219, rs4752220 and rs7091672) were significantly correlated with the toxicities tested (neutropenia, anemia, thrombocytopenia, emesis and hepatotoxicity). In addition, rs10510050 was significantly correlated with thrombocytopenia, emesis and hepatotoxicity. None of the 5 non-positively selected SNPs was correlated with the 5 toxicities. Conclusion: The positively selected SNPs of eIF3a are significantly correlated with platinum-based chemotherapy toxicities in Chinese NSCLC patients.
引用
收藏
页码:375 / 384
页数:10
相关论文
共 50 条
  • [21] Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement
    Li, Dan-Juan
    Xiao, Dong
    [J]. BMC CANCER, 2017, 17
  • [22] Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review
    Afifah, Nadiya Nurul
    Diantini, Ajeng
    Intania, Ruri
    Abdulah, Rizky
    Barliana, Melisa, I
    [J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2020, 13 : 427 - 444
  • [23] The association of genetic variations in DNA repair pathways with severe toxicities in NSCLC patients undergoing platinum-based chemotherapy
    Zheng, Yi
    Deng, Zheng
    Yin, Jiye
    Wang, Shiming
    Lu, Daru
    Wen, Xiaoke
    Li, Xiangping
    Xiao, Di
    Hu, Chengping
    Chen, Xiang
    Zhang, Wei
    Zhou, Honghao
    Liu, Zhaoqian
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (11) : 2336 - 2347
  • [24] The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy
    He, Jia
    Wang, Zhan
    Wang, Ying
    Zou, Ting
    Li, Xiang-Ping
    Cao, Lei
    Chen, Juan
    [J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 1193 - 1203
  • [25] Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC
    Wu, Fenglei
    Hu, Nan
    Li, Yu
    Bian, Baoxiang
    Xu, Guanghui
    Zheng, Yitong
    [J]. CELLULAR ONCOLOGY, 2012, 35 (03) : 175 - 180
  • [26] The Role of ADCY1 in Regulating the Sensitivity of Platinum-Based Chemotherapy in NSCLC
    Zou, Ting
    Liu, Jun-Yan
    Liu, Zhao-Qian
    Xiao, Di
    Chen, Juan
    [J]. PHARMACEUTICALS, 2024, 17 (09)
  • [27] Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
    Zou, Ting
    Liu, Jun-Yan
    Qin, Qun
    Guo, Jie
    Zhou, Wen-Zhi
    Li, Xiang-Ping
    Zhou, Hong-Hao
    Chen, Juan
    Liu, Zhao-Qian
    [J]. BIOMEDICINES, 2023, 11 (12)
  • [28] Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy
    Weitzner, Omar
    Yagur, Yael
    Kadan, Yfat
    Beiner, Mario E.
    Fishman, Ami
    Ben Ezry, Emilie
    Komem, Daphna Amitai
    Helpman, Limor
    [J]. ONCOLOGIST, 2019, 24 (12) : E1471 - E1475
  • [29] Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine
    Yin, Ji-Ye
    Li, Xi
    Zhou, Hong-Hao
    Liu, Zhao-Qian
    [J]. PHARMACOGENOMICS, 2016, 17 (12) : 1365 - 1378
  • [30] Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response
    Gong, Wei-Jing
    Yin, Ji-Ye
    Li, Xiang-Ping
    Fang, Chao
    Xiao, Di
    Zhang, Wei
    Zhou, Hong-Hao
    Li, Xi
    Liu, Zhao-Qian
    [J]. TUMOR BIOLOGY, 2016, 37 (06) : 8349 - 8358